Visual Abstract

This prospective observational study compared the performance of the Dexcom G6 continuous glucose monitor (CGM) and point-of-care (POC) blood glucose (BG) testing in a non-ICU setting.

Methods: We placed a blinded Dexcom G6 on 91 insulin-treated adult medicine and surgery patients (age 57±10 years, BMI 35±10 kg/m2, HbA1c 9.2±2.1%), with a median hospital length of stay of 8.0 days (min, max 2.0, 33.0), and total daily insulin dose of 45±29 U/day, to compare inpatient glycemic control metrics as measured by POC and CGM.

Results: CGM mean absolute relative difference (MARD) was 12.5% with 98.9% of glucose values falling into Clark Error Grid zone A or B for matched POC and CGM glucose pairs. Compared to POC, a greater percentage of patients were identified by CGM to have hypoglycemia <70 mg/dl (47% vs. 27%), nocturnal hypoglycemia (22% vs. 1%), prolonged hypoglycemia > 2 hours (5.6% vs. 0%) and severe hyperglycemia >250 mg/dl (73% vs. 66%). Differences in glycemic metrics between POC and CGM are shown in the Table.

Conclusion: Dexcom G6 detected more overall, nocturnal and prolonged hypoglycemia in hospitalized non-ICU patients with diabetes than POC testing. Future prospective studies are needed to determine the benefits of real-time CGM in improving inpatient diabetes care and in reducing hypoglycemia and hyperglycemia in hospitalized patients with diabetes.


G. M. Davis: None. P. Vellanki: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc. F. J. Pasquel: Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Research Support; Self; Dexcom, Inc., Merck & Co., Inc. L. Peng: None. G. E. Umpierrez: Research Support; Self; AstraZeneca, Dexcom, Inc., Novo Nordisk. A. Migdal: None. M. A. Urrutia: None. K. Zamudio-coronado: None. M. C. Perez-guzman: None. B. S. Albury: None. S. Cardona: None. R. J. Galindo: Consultant; Self; Abbott Diabetes, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk, Sanofi US, Valeritas, Inc., Research Support; Self; Dexcom, Inc., Novo Nordisk. T. Idrees: None.


Dexcom, Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at